A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Everolimus (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ROPETAR
- 18 Dec 2013 Planned End Date changed from 1 Feb 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 26 Nov 2012 Planned end date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 05 Dec 2011 Actual initiation date (Nov 2011) added as reported by ClinicalTrials.gov.